"Albuterol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
| Descriptor ID |
D000420
|
| MeSH Number(s) |
D02.033.100.291.057 D02.092.063.291.057 D02.092.471.683.061
|
| Concept/Terms |
Albuterol- Albuterol
- Salbutamol
- 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol
|
Below are MeSH descriptors whose meaning is more general than "Albuterol".
Below are MeSH descriptors whose meaning is more specific than "Albuterol".
This graph shows the total number of publications written about "Albuterol" by people in this website by year, and whether "Albuterol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 4 | 0 | 4 |
| 2007 | 0 | 1 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Albuterol" by people in Profiles.
-
Asthma Care Protocol Implementation in the Pediatric Intensive Care Unit. Crit Care Nurs Clin North Am. 2023 Sep; 35(3):337-346.
-
Deposition pattern of heliox-driven bronchodilator aerosol in the airways of stable asthmatics. J Asthma. 2005 Sep; 42(7):583-6.
-
Tissue specific effects of the beta 2-adrenergic agonist salbutamol on LPS-induced IFN-gamma, IL-10 and TGF-beta responses in vivo. J Neuroimmunol. 2004 May; 150(1-2):3-9.
-
The beta 2-adrenergic agonist salbutamol potentiates oral induction of tolerance, suppressing adjuvant arthritis and antigen-specific immunity. J Immunol. 2002 Nov 01; 169(9):5028-35.
-
Exercise-induced asthma. N Engl J Med. 1998 Dec 10; 339(24):1783-4; author reply 1785.
-
Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. Mol Pharmacol. 1996 Sep; 50(3):692-9.